DDInter1078 DDInter927
Lisdexamfetamine is a prodrug of [dextroamphetamine], a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisdexamfetamine works to treat attention deficit hyperactivity disorder and binge eating disorder by blocking dopamine and norepinephrine reuptake and increasing their levels in the extraneuronal space.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Lacosamide
Lisdexamfetamine {u} (Compound) resembles {v} (Compound) Amphetamine
Lisdexamfetamine {u} (Compound) binds {v} (Gene) SLC6A3
Lisdexamfetamine {u} (Compound) palliates {v} (Disease) attention deficit hyperactivity disorder
Lisdexamfetamine {u} (Compound) is included by {v} (Pharmacologic Class) Central Nervous System Stimulation
Lisdexamfetamine {u} (Compound) causes {v} (Side Effect) Psychotic disorder
Lisdexamfetamine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pseudoephedrine
Lisdexamfetamine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ammonium chloride
Lisdexamfetamine {u} may lead to a major life threatening interaction when taken with {v} Arsenic trioxide
Lisdexamfetamine (Compound) resembles Lacosamide (Compound)
Lisdexamfetamine (Compound) resembles Amphetamine (Compound)
Lisdexamfetamine (Compound) binds SLC6A3 (Gene)
Lisdexamfetamine (Compound) palliates attention deficit hyperactivity disorder (Disease)
Lisdexamfetamine (Compound) is included by Central Nervous System Stimulation (Pharmacologic Class)
Lisdexamfetamine (Compound) causes Psychotic disorder (Side Effect)
Lisdexamfetamine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine
Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Ammonium chloride
Lisdexamfetamine may lead to a major life threatening interaction when taken with Arsenic trioxide